Search

Your search keyword '"Fanti, Stefano"' showing total 3,031 results
Start Over Author "Fanti, Stefano"

Refine your results

more »

more »

more »

more »

more »
3,031 results on '"Fanti, Stefano"'

4. Guiding principles on the education and practice of theranostics

Author

Pascual, Thomas N. B., Paez, Diana, Iagaru, Andrei, Gnanasegaran, Gopi, Lee, Sze Ting, Sathekge, Mike, Buatti, John M., Giammarile, Francesco, Al-Ibraheem, Akram, Pardo, Manuela Arevalo, Baum, Richard P., De Bari, Berardino, Ben-Haim, Simona, Blay, Jean-Yves, Brink, Anita, Estrada-Lobato, Enrique, Fanti, Stefano, Golubic, Anja Tea, Hatazawa, Jun, Israel, Ora, Kiess, Ana, Knoll, Peter, Louw, Lizette, Mariani, Giuliano, Mirzaei, Siroos, Orellana, Pilar, Prior, John O., Urbain, Jean-Luc, Vichare, Shrikant, Vinjamuri, Sobhan, Virgolini, Irene, and Scott, Andrew M.

Published
2024
Full Text
View/download PDF

5. Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis

Author

Trapp, Christian, Aebersold, Daniel M., Belka, Claus, Casuscelli, Jozefina, Emmett, Louise, Eze, Chukwuka, Fanti, Stefano, Farolfi, Andrea, Fendler, Wolfgang, Grosu, Anca-Ligia, Guckenberger, Matthias, Hruby, George, Kirste, Simon, Koerber, Stefan A., Kroeze, Stephanie, Peeken, Jan C., Rogowski, Paul, Scharl, Sophia, Shelan, Mohamed, Spohn, Simon K. B., Strouthos, Iosif, Unterrainer, Lena, Vogel, Marco, Wiegel, Thomas, Zamboglou, Constantinos, and Schmidt-Hegemann, Nina-Sophie

Published
2024
Full Text
View/download PDF

7. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

Author

Voltin, Conrad-Amadeus, Paccagnella, Andrea, Winkelmann, Michael, Heger, Jan-Michel, Casadei, Beatrice, Beckmann, Laura, Herrmann, Ken, Dekorsy, Franziska J., Kutsch, Nadine, Borchmann, Peter, Fanti, Stefano, Kunz, Wolfgang G., Subklewe, Marion, Kobe, Carsten, Zinzani, Pier Luigi, Stelljes, Matthias, Roth, Katrin S., Drzezga, Alexander, Noppeney, Richard, Rahbar, Kambiz, Reinhardt, H. Christian, von Tresckow, Bastian, Seifert, Robert, Albring, Jörn C., Blumenberg, Viktoria, Farolfi, Andrea, Flossdorf, Sarah, Gödel, Philipp, and Hanoun, Christine

Published
2024
Full Text
View/download PDF

9. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).

Author

Kratochwil, Clemens, Fendler, Wolfgang P, Eiber, Matthias, Hofman, Michael S, Emmett, Louise, Calais, Jeremie, Osborne, Joseph R, Iravani, Amir, Koo, Phillip, Lindenberg, Liza, Baum, Richard P, Bozkurt, Murat Fani, Delgado Bolton, Roberto C, Ezziddin, Samer, Forrer, Flavio, Hicks, Rodney J, Hope, Thomas A, Kabasakal, Levent, Konijnenberg, Mark, Kopka, Klaus, Lassmann, Michael, Mottaghy, Felix M, Oyen, Wim JG, Rahbar, Kambiz, Schoder, Heiko, Virgolini, Irene, Bodei, Lisa, Fanti, Stefano, Haberkorn, Uwe, and Hermann, Ken

Subjects
Humans, Lutetium, Heterocyclic Compounds, 1-Ring, Prostate-Specific Antigen, Dipeptides, Radiopharmaceuticals, Treatment Outcome, Nuclear Medicine, Male, Prostatic Neoplasms, Castration-Resistant, EANM/SNMMI, PSMA, [177Lu]Lu-PSMA-617, Aging, Urologic Diseases, Prostate Cancer, Cancer, Good Health and Well Being, EANM, SNMMI, [Lu-177]Lu-PSMA-617, Other Physical Sciences, Clinical Sciences, Nuclear Medicine & Medical Imaging
Abstract

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [177Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that 177Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from 177Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [177Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.

Published
2023

10. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy

Author

Adebahr, Sonja, Althaus, Alexander, Scharl, Sophia, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Lanzafame, Helena, Trapp, Christian, Koerber, Stefan A., Peeken, Jan C., Vogel, Marco M. E., Vrachimis, Alexis, Spohn, Simon K. B., Grosu, Anca-Ligia, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Hruby, George, Emmett, Louise, Belka, Claus, Schmidt-Hegemann, Nina-Sophie, Henkenberens, Christoph, Aebersold, Daniel M., Wiegel, Thomas, Afshar-Oromieh, Ali, Zamboglou, Constantinos, and Shelan, Mohamed

Published
2024
Full Text
View/download PDF

11. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.

Author

Fendler, Wolfgang P, Eiber, Matthias, Beheshti, Mohsen, Bomanji, Jamshed, Calais, Jeremie, Ceci, Francesco, Cho, Steve Y, Fanti, Stefano, Giesel, Frederik L, Goffin, Karolien, Haberkorn, Uwe, Jacene, Heather, Koo, Phillip J, Kopka, Klaus, Krause, Bernd J, Lindenberg, Liza, Marcus, Charles, Mottaghy, Felix M, Oprea-Lager, Daniela E, Osborne, Joseph R, Piert, Morand, Rowe, Steven P, Schöder, Heiko, Wan, Simon, Wester, Hans-Jürgen, Hope, Thomas A, and Herrmann, Ken

Subjects
Humans, Prostatic Neoplasms, Gallium Radioisotopes, Edetic Acid, Oligopeptides, Male, Positron Emission Tomography Computed Tomography, Guideline, PET, PSMA, Prostate cancer, Restaging, Staging, Biomedical Imaging, Urologic Diseases, Aging, Prostate Cancer, Cancer, Other Physical Sciences, Clinical Sciences, Nuclear Medicine & Medical Imaging
Abstract

Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.

Published
2023

14. Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach

Author

Asmundo, Luigi, Ambrosini, Valentina, Anderson, Mark A., Fanti, Stefano, Bradley, William R., Campana, Davide, Mojtahed, Amirkasra, Chung, Ryan, Mcdermott, Shaunagh, Digumarthy, Subba, Ursprung, Stephan, Nikolau, Konstantin, Fintelmann, Florian J., Blake, Michael, Fernandez-del Castillo, Carlos, Qadan, Motaz, Pandey, Ankur, Clark, Jeffrey W., and Catalano, Onofrio A.

Published
2024
Full Text
View/download PDF

15. Imaging of Neuroendocrine Neoplasms; Principles of Treatment Strategies. What Referring Clinicians Want to Know

Author

Asmundo, Luigi, Ambrosini, Valentina, Mojtahed, Amirkasra, Fanti, Stefano, Ferrone, Cristina, Hesami, Mina, Sertic, Madeleine, Najmi, Zahra, Furtado, Felipe S., Dhami, Ranjodh S., Anderson, Mark A., Samir, Anthony, Sharma, Amita, Campana, Davide, Ursprung, Stephan, Nikolau, Konstantin, Domachevsky, Liran, Blake, Michael A., Norris, Evan C., Clark, Jeffrey W., and Catalano, Onofrio A.

Published
2024
Full Text
View/download PDF

16. State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms

Author

Ambrosini, Valentina, Fortunati, Emilia, Fanti, Stefano, Ursprung, Stephan, Asmundo, Luigi, OʼShea, Aileen, Kako, Bashar, Lee, Susanna, Furtado, Felipe S., Blake, Michael, Goiffon, Reece J., Najmi, Zahra, Hesami, Mina, Murakami, Takaaki, Domachevsky, Liran, and Catalano, Onofrio A.

Published
2024
Full Text
View/download PDF

17. CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study

Author

Pensato, Umberto, Amore, Giulia, Muccioli, Lorenzo, Sammali, Susanna, Rondelli, Francesca, Rinaldi, Rita, D’Angelo, Roberto, Nicodemo, Marianna, Mondini, Susanna, Sambati, Luisa, Asioli, Gian Maria, Rossi, Simone, Santoro, Rossella, Cretella, Lucia, Ferrari, Susy, Spinardi, Luca, Faccioli, Luca, Fanti, Stefano, Paccagnella, Andrea, Pierucci, Elisabetta, Casadei, Beatrice, Pellegrini, Cinzia, Zinzani, Pier Luigi, Bonafè, Massimiliano, Cortelli, Pietro, Bonifazi, Francesca, and Guarino, Maria

Published
2023
Full Text
View/download PDF

20. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer

Author

Oprea-Lager, Daniela-Elena, MacLennan, Steven, Bjartell, Anders, Briganti, Alberto, Burger, Irene A., de Jong, Igle, De Santis, Maria, Eberlein, Uta, Emmett, Louise, Fizazi, Karim, Gillessen, Silke, Herrmann, Ken, Heskamp, Sandra, Iagaru, Andrei, Jereczek-Fossa, Barbara Alicja, Kunikowska, Jolanta, Lam, Marnix, Nanni, Cristina, O'Sullivan, Joe M., Panebianco, Valeria, Sala, Evis, Sathekge, Mike, Sosnowski, Roman, Tilki, Derya, Tombal, Bertrand, Treglia, Giorgio, Tunariu, Nina, Walz, Jochen, Yakar, Derya, Dierckx, Rudi, Sartor, Oliver, and Fanti, Stefano

Published
2024
Full Text
View/download PDF

22. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml

Author

Solomonidou, Nantia, Germanou, Daphnie, Strouthos, Iosif, Karagiannis, Efstratios, Farolfi, Andrea, Koerber, Stefan A., Debus, Juergen, Peeken, Jan C., Vogel, Marco E., Vrachimis, Alexis, Spohn, Simon K. B., Shelan, Mohamed, Aebersold, Daniel, Grosu, Anca-Ligia, Ceci, Francesco, Kroeze, Stephanie G. C., Guckenberger, Matthias, Fanti, Stefano, Belka, Claus, Hruby, George, Scharl, S., Wiegel, Thomas, Bartenstein, Peter, Henkenberens, Christoph, Emmett, Louise, Schmidt-Hegemann, Nina Sophie, Ferentinos, Konstantinos, and Zamboglou, Constantinos

Published
2023
Full Text
View/download PDF

23. Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial

Author

Guido, Alessandra, Cuicchi, Dajana, Castellucci, Paolo, Cellini, Francesco, Di Fabio, Francesca, Llimpe, Fabiola Lorena Rojas, Strigari, Lidia, Buwenge, Milly, Cilla, Savino, Deodato, Francesco, Macchia, Gabriella, Galietta, Erika, Golfieri, Rita, Ardizzoni, Andrea, Zagari, Rocco Maurizio, Fanti, Stefano, Poggioli, Gilberto, Fuccio, Lorenzo, and Morganti, Alessio G.

Published
2023
Full Text
View/download PDF

24. Normal Anatomy

Author

Nanni, Cristina, Fanti, Stefano, Zanoni, Lucia, Golfieri, Rita, Cappelli, Alberta, Cocozza, Maria Adriana, Bartalena, Laura, Nanni, Cristina, editor, Fanti, Stefano, editor, Zanoni, Lucia, editor, and Golfieri, Rita, editor

Published
2022
Full Text
View/download PDF

25. Musculoskeletal

Author

Nanni, Cristina, Fanti, Stefano, Zanoni, Lucia, Golfieri, Rita, Mosconi, Cristina, Cattabriga, Arrigo, Nanni, Cristina, editor, Fanti, Stefano, editor, Zanoni, Lucia, editor, and Golfieri, Rita, editor

Published
2022
Full Text
View/download PDF

26. Pelvis

Author

Nanni, Cristina, Fanti, Stefano, Zanoni, Lucia, Golfieri, Rita, Cappelli, Alberta, Cattabriga, Arrigo, Nanni, Cristina, editor, Fanti, Stefano, editor, Zanoni, Lucia, editor, and Golfieri, Rita, editor

Published
2022
Full Text
View/download PDF

27. Thorax

Author

Nanni, Cristina, Fanti, Stefano, Zanoni, Lucia, Golfieri, Rita, Brocchi, Stefano, Brandi, Nicolò, Parmeggiani, Anna, Nanni, Cristina, editor, Fanti, Stefano, editor, Zanoni, Lucia, editor, and Golfieri, Rita, editor

Published
2022
Full Text
View/download PDF

28. Abdomen

Author

Nanni, Cristina, Fanti, Stefano, Zanoni, Lucia, Golfieri, Rita, Mosconi, Cristina, Parmeggiani, Anna, Brandi, Nicolò, Nanni, Cristina, editor, Fanti, Stefano, editor, Zanoni, Lucia, editor, and Golfieri, Rita, editor

Published
2022
Full Text
View/download PDF

29. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Author

Ceci, Francesco, Oprea-Lager, Daniela E, Emmett, Louise, Adam, Judit A, Bomanji, Jamshed, Czernin, Johannes, Eiber, Matthias, Haberkorn, Uwe, Hofman, Michael S, Hope, Thomas A, Kumar, Rakesh, Rowe, Steven P, Schwarzenboeck, Sarah M, Fanti, Stefano, and Herrmann, Ken

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Biomedical Imaging, Urologic Diseases, Prostate Cancer, Humans, Male, Nuclear Medicine, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Prostatic Neoplasms, Reproducibility of Results, PSMA-PET, PSMA prostate cancer, Structured report, Consensus panel, EANM guidelines, Prostate cancer guidelines, Other Physical Sciences, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

RationaleThe development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the data reproducibility within clinical trials. Finally, guidelines in PSMA-PET interpretation are needed to communicate the exact location of findings to referring physicians, to support clinician therapeutic management decisions.MethodsA panel of worldwide experts in PSMA-PET was established. Panelists were selected based on their expertise and publication record in the diagnosis or treatment of PCa, in their involvement in clinical guidelines and according to their expertise in the clinical application of radiolabeled PSMA inhibitors. Panelists were actively involved in all stages of a modified, nonanonymous, Delphi consensus process.ResultsAccording to the findings obtained by modified Delphi consensus process, panelist recommendations were implemented in a structured report for PSMA-PET.ConclusionsThe E-PSMA standardized reporting guidelines, a document supported by the European Association of Nuclear Medicine (EANM), provide consensus statements among a panel of experts in PSMA-PET imaging, to develop a structured report for PSMA-PET in prostate cancer and to harmonize diagnostic interpretation criteria.

Published
2021

31. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty

Author

Bamias, Aristotelis, Stenzl, Arnulf, Brown, Stephanie L., Albiges, Laurence, Babjuk, Marko, Birtle, Alison, Briganti, Alberto, Burger, Maximilian, Choudhury, Ananya, Colecchia, Maurizio, De Santis, Maria, Fanti, Stefano, Fonteyne, Valérie, Gallucci, Michele, Rivas, Juan Gómez, Huddart, Robert, Junker, Kerstin, Kroeze, Stephanie, Loriot, Yohann, Merseburger, Axel, Montironi, Rodolfo, Necchi, Andrea, Oing, Christoph, Oldenburg, Jan, Ost, Piet, Pinkawa, Michael, Ribal, Maria J., Rouprêt, Morgan, Thoeny, Harriet, Zilli, Thomas, and Hoskin, Peter

Published
2023
Full Text
View/download PDF

34. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

Author

Scharl, Sophia, Zamboglou, Constantinos, Strouthos, Iosif, Farolfi, Andrea, Serani, Francesca, Lanzafame, Helena, Giuseppe Morganti, Alessio, Trapp, Christian, Koerber, Stefan A., Debus, Jürgen, Peeken, Jan C., Vogel, Marco M.E., Vrachimis, Alexis, Spohn, Simon K.B., Ruf, Juri, Grosu, Anca-Ligia, Ceci, Francesco, Fendler, Wolfgang P., Bartenstein, Peter, Kroeze, Stephanie G.C., Guckenberger, Matthias, Krafcsik, Manuel, Klopscheck, Christina, Fanti, Stefano, Hruby, George, Emmett, Louise, Belka, Claus, Stief, Christian, Schmidt-Hegemann, Nina-Sophie, Henkenberens, Christoph, Mayer, Benjamin, Miksch, Jonathan, Shelan, Mohamed, Aebersold, Daniel M., Thamm, Reinhard, and Wiegel, Thomas

Published
2023
Full Text
View/download PDF

36. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial

Author

Polverari, Giulia, Ceci, Francesco, Passera, Roberto, Crane, Jacquelyn, Du, Lin, Li, Gang, Fanti, Stefano, Bernthal, Nicholas, Eilber, Fritz C, Allen-Auerbach, Martin, Czernin, Johannes, Calais, Jeremie, and Federman, Noah

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Rare Diseases, Pediatric, Pediatric Research Initiative, Pediatric Cancer, Prevention, Biomedical Imaging, Clinical Research, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, [F-18]FDG, PET, CT, Sarcoma, Neoadjuvant chemotherapy, Therapy response, Pediatrics, PET/CT, [18F]FDG, Medical Biochemistry and Metabolomics, Clinical sciences, Oncology and carcinogenesis
Abstract

IntroductionThis is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [18F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX).MethodsBone or soft tissue sarcoma patients with (1) baseline [18F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only.ResultsThirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p

Published
2020

37. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis

Author

Spohn, Simon K. B., Farolfi, Andrea, Schandeler, Sarah, Vogel, Marco M. E., Ruf, Juri, Mix, Michael, Kirste, Simon, Ceci, Francesco, Fanti, Stefano, Lanzafame, Helena, Serani, Francesca, Gratzke, Christian, Sigle, August, Combs, Stephanie E., Bernhardt, Denise, Gschwend, Juergen E., Buchner, Josef A., Trapp, Christian, Belka, Claus, Bartenstein, Peter, Unterrainer, Lena, Unterrainer, Marcus, Eiber, Matthias, Nekolla, Stephan G., Schiller, Kilian, Grosu, Anca L., Schmidt-Hegemann, Nina-Sophie, Zamboglou, Constantinos, and Peeken, Jan C.

Published
2022
Full Text
View/download PDF

38. Head and Neck

Author

Nanni, Cristina, Fanti, Stefano, Zanoni, Lucia, Nanni, Cristina, editor, Fanti, Stefano, editor, Zanoni, Lucia, editor, and Golfieri, Rita, editor

Published
2022
Full Text
View/download PDF

39. Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

Author

Zamagni, Elena, Oliva, Stefania, Gay, Francesca, Capra, Andrea, Rota-Scalabrini, Delia, D'Agostino, Mattia, Belotti, Angelo, Galli, Monica, Racca, Manuela, Zambello, Renato, Gamberi, Barbara, Albano, Domenico, Bertamini, Luca, Versari, Annibale, Grasso, Mariella, Sgherza, Nicola, Priola, Claudia, Fioritoni, Francesca, Patriarca, Francesca, De Cicco, Gabriella, Villanova, Tania, Pascarella, Anna, Zucchetta, Pietro, Tacchetti, Paola, Fanti, Stefano, Mancuso, Katia, Barbato, Simona, Boccadoro, Mario, Musto, Pellegrino, Cavo, Michele, and Nanni, Cristina

Published
2023
Full Text
View/download PDF

40. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raja, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark A., Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

41. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Author

Seifert, Robert, Emmett, Louise, Rowe, Steven P., Herrmann, Ken, Hadaschik, Boris, Calais, Jeremie, Giesel, Frederik L., Reiter, Robert, Maurer, Tobias, Heck, Matthias, Gafita, Andrei, Morris, Michael J., Fanti, Stefano, Weber, Wolfgang A., Hope, Thomas A., Hofman, Michael S., Fendler, Wolfgang Peter, and Eiber, Matthias

Published
2023
Full Text
View/download PDF

42. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

Author

Farolfi, Andrea, Ilhan, Harun, Gafita, Andrei, Calais, Jeremie, Barbato, Francesco, Weber, Manuel, Afshar-Oromieh, Ali, Spohn, Fabian, Wetter, Axel, Rischpler, Christoph, Hadaschik, Boris, Pianori, Davide, Fanti, Stefano, Haberkorn, Uwe, Eiber, Matthias, Herrmann, Ken, and Fendler, Wolfgang Peter

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Cancer, Biomedical Imaging, Aging, Prostate Cancer, Aetiology, 2.1 Biological and endogenous factors, Antigens, Surface, Glutamate Carboxypeptidase II, Humans, Image Processing, Computer-Assisted, Lymph Node Excision, Male, Positron-Emission Tomography, Prostatic Neoplasms, Salvage Therapy, Treatment Failure, PET, prostate cancer, PSA persistence, PSMA, salvage lymph node dissection, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvage lymph node dissection (SLND) and pre-procedure and post-procedure prostate-specific membrane antigen (PSMA) ligand PET. Methods: Sixteen patients were included in this multicenter study. The inclusion criteria were PSMA PET performed for biochemical recurrence before SLND (pre-SLND PET) and repeat PSMA PET performed for a persistently elevated PSA level (≥0.1 ng/mL) at least 6 wk after SLND (post-SLND PET). Image analysis was performed by 3 independent nuclear medicine physicians applying the molecular imaging TNM system PROMISE. Lesions were confirmed by histopathology, presence on correlative CT/MRI/bone scanning, or PSA response after focal therapy. Results: Post-SLND PET identified prostate cancer lesions in 88% (14/16) of patients with PSA persistence after SLND. Median PSA was 1.2 ng/mL (interquartile range, 0.6-2.8 ng/mL). Disease was confined to the pelvis in 56% of patients (9/16), and most of these men had common iliac (6/16, 38%) and internal iliac lymph node metastases (6/16, 38%). Extrapelvic disease was detected in 31% of patients (5/16). In pre- and post-SLND PET comparison, 10 of 16 had at least one lesion already detected at baseline (63% PET persistence), 4 of 16 had new lesions only (25% PET recurrence), and 2 had no disease on post-SLND PET. All validated regions (11 regions in 9 patients) were true-positive. Nine of 14 (64%) patients underwent repeat local therapies after SLND (7/14 radiotherapy, 2/14 surgery). Conclusion: SLND of pelvic nodal metastases was often not complete according to PSMA PET. About two thirds of patients had PET-positive nodal disease after SLND already seen on pre-SLND PSMA PET. Notably, about one quarter of patients had new lesions, not detected by presurgical PSMA PET.

Published
2020

43. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Author

Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Chi, Kim N, Clarke, Noel, Davis, Ian D, de Bono, Johann, Drake, Charles G, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Heinrich, Daniel, Higano, Celestia Tia S, Hofman, Michael S, Hussain, Maha, James, Nicolas, Kanesvaran, Ravindran, Kantoff, Philip, Khauli, Raja B, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Chris, Poon, Darren MC, Pritchard, Colin C, Reiter, Robert E, Roach, Mack, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Small, Eric, Smith, Matthew, Soule, Howard, Sternberg, Cora N, Steuber, Thomas, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tombal, Bertrand, Türkeri, Levent, van Oort, Inge, Zapatero, Almudena, and Omlin, Aurelius

Subjects
Cancer, Urologic Diseases, Aging, Prostate Cancer, Good Health and Well Being, Bone Neoplasms, Humans, Male, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Practice Guidelines as Topic, Prostate-Specific Antigen, Prostatic Neoplasms, Advanced prostate cancer, High-risk localised prostate cancer, Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Oligometastatic prostate cancer, Progression-free survival, Overall survival, Prostate cancer treatment, Imaging, Genetics, Tumour genomic profiling, Castration-naïve prostate cancer, Clinical Sciences, Urology & Nephrology
Abstract

BackgroundInnovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.ObjectiveTo present the results from the APCCC 2019.Design, setting, and participantsSimilar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions.Outcome measurements and statistical analysisThe panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process.Results and limitationsPanellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material.ConclusionsThese voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials.Patient summaryThe Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.

Published
2020

44. Teaching Cases in Nuclear Oncology: Pancreatic Cancer

Author

Lorenzoni, Alice, Alessi, Alessandra, Crippa, Flavio, Tabacchi, Elena, Nanni, Cristina, Bossert, Irene, Maffione, Anna Margherita, Fanti, Stefano, Olivari, Laura, Chiti, Arturo, Volterrani, Duccio, editor, Erba, Paola A., editor, Strauss, H. William, editor, Mariani, Giuliano, editor, and Larson, Steven M., editor

Published
2022
Full Text
View/download PDF

46. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

47. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence

Author

Bianchi, Lorenzo, Castellucci, Paolo, Farolfi, Andrea, Droghetti, Matteo, Artigas, Carlos, Leite, Jose, Corona, Paola, Shagera, Qaid Ahmed, Moreira, Renata, González, Christian, Queiroz, Marcelo, de Galiza Barbosa, Felipe, Schiavina, Riccardo, Deandreis, Desiree, Fanti, Stefano, and Ceci, Francesco

Published
2023
Full Text
View/download PDF

49. Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people

Author

Taglieri, Nevio, Bonfiglioli, Rachele, Bon, Isabella, Malosso, Pietro, Corovic, Andrej, Bruno, Matteo, Le, Elizabeth, Granozzi, Bianca, Palmerini, Tullio, Ghetti, Gabriele, Tamburello, Martina, Bruno, Antonio Giulio, Saia, Francesco, Tarkin, Jason M., Rudd, James H. F., Calza, Leonardo, Fanti, Stefano, Re, Maria Carla, and Galié, Nazzareno

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results